MFDS Expands Silicone Sealants Regulation in Korea: ISO 10993-5 Now Mandatory

Korea’s Ministry of Food and Drug Safety (MFDS) announced new regulatory requirements for silicone sealants on May 5, 2026 — effective August 1, 2026. This update directly affects manufacturers, importers, and distributors supplying products for medical facilities, cleanrooms, and food-grade piping systems. The change signals a tightening of biocompatibility oversight in non-implantable medical-adjacent applications, making it critical for stakeholders in adhesives, construction chemicals, and regulated industrial supply chains to reassess compliance pathways.

Event Overview

On May 5, 2026, the Korean Ministry of Food and Drug Safety (MFDS) issued an official notice requiring, starting August 1, 2026, that all silicone sealants used in medical facilities, cleanrooms, and food-grade piping systems must provide a certified ISO 10993-5 cytotoxicity test report. This requirement applies to every imported batch, with no exemptions. In addition to existing K-REACH registration obligations, this represents a new, standalone conformity condition. As of the announcement date, only seven Chinese silicone sealant manufacturers have completed and registered such testing with MFDS.

Which Subsectors Are Affected

Direct Importers and Exporters

Importers placing silicone sealants into the Korean market for the specified end uses must now submit ISO 10993-5 test reports for each shipment. Since the requirement is per-batch and non-exempt, customs clearance may be delayed or denied without valid documentation. This increases administrative burden and introduces potential supply chain discontinuity if testing is not pre-arranged.

Manufacturers and Formulators

Producers — especially those based in China and other exporting countries — face direct compliance responsibility if their products fall within the scope. Unlike K-REACH, which often allows downstream importer-led registration, ISO 10993-5 testing is product-specific and typically initiated by the manufacturer. With only seven Chinese firms currently compliant, most producers lack validated test data, meaning formulation changes or requalification may be needed before export.

Contract Manufacturers and Toll Blenders

Entities producing under private label or OEM arrangements are affected when the final product is marketed for medical, cleanroom, or food-piping use in Korea. Even if the base polymer is supplied by a third party, the finished sealant formulation must undergo ISO 10993-5 testing. Responsibility for test validity rests with the entity named on the Korean import declaration — often the brand owner or local authorized representative.

Distributors and Channel Partners

Distributors handling multiple brands must verify whether each SKU intended for regulated Korean applications meets the new requirement. Stock rotation, labeling, and technical documentation (e.g., CoA, test reports) now require explicit alignment with ISO 10993-5. Failure to distinguish compliant vs. non-compliant SKUs may lead to inadvertent non-conforming shipments.

What Relevant Companies or Practitioners Should Focus On — And How to Respond

Monitor MFDS official guidance for implementation details

While the effective date (August 1, 2026) and scope are confirmed, MFDS has not yet published detailed guidance on accepted test laboratories, report format, validity period, or transitional provisions. Companies should track MFDS announcements and consult Korea’s official regulatory portal for updates — particularly regarding whether historical ISO 10993-5 reports (e.g., from prior medical device submissions) can be reused.

Identify and prioritize SKUs falling under the defined use cases

The regulation applies only to silicone sealants used in three settings: medical facilities, cleanrooms, and food-grade piping. It does not apply to general construction, automotive, or electronics sealing. Companies should audit product positioning, marketing claims, safety data sheets (SDS), and customer application statements to determine which SKUs trigger the requirement — avoiding over-compliance while ensuring coverage where mandated.

Distinguish between regulatory signal and operational readiness

This requirement reflects a policy shift toward harmonizing material safety standards with global medical device frameworks — but it is not a full medical device classification. Analysis shows MFDS is applying ISO 10993-5 as a targeted biocompatibility gate, not imposing full ISO 10993 series evaluation. That means current focus remains narrowly on cytotoxicity, not sensitization, genotoxicity, or implantation testing.

Initiate test planning and lab engagement now

ISO 10993-5 testing typically requires 4–8 weeks, depending on lab capacity and sample preparation. Given the August 1, 2026 deadline and limited availability of accredited labs accepting international submissions, companies should secure testing slots immediately. Priority should go to SKUs with active Korean sales pipelines or pending tenders in healthcare infrastructure projects.

Editorial Perspective / Industry Observation

Observably, this MFDS move is less about immediate enforcement disruption and more about signaling long-term regulatory convergence. While only seven Chinese manufacturers are currently listed as compliant, the requirement itself is technically straightforward — cytotoxicity testing is widely available and well-standardized. From an industry perspective, this appears to be an early-stage calibration: aligning industrial sealants with foundational biocompatibility expectations where human/environmental contact is frequent and controlled. It is better understood as a procedural tightening than a substantive reclassification — yet one that reveals growing scrutiny of ‘indirect medical’ materials. Continued attention is warranted, especially as MFDS may extend similar logic to other polymer-based construction products in future notices.

Conclusion

This regulatory update marks a targeted expansion of biocompatibility oversight for silicone sealants in Korea — not a broad-based overhaul, but a clear boundary-setting action with tangible operational consequences. For affected businesses, the priority is not speculation about future rules, but precise scoping, timely test execution, and documentation discipline. The requirement is best interpreted not as a barrier, but as a defined, actionable compliance checkpoint aligned with internationally recognized safety science.

Information Source

Primary source: Korea Ministry of Food and Drug Safety (MFDS), official notice dated May 5, 2026. Ongoing implementation details — including list of accredited testing laboratories and report submission procedures — remain subject to further MFDS publication and are under observation.